RAPT Therapeutics (RAPT) shares were up 89% premarket Monday after the company and Shanghai Jemincare said Monday they have signed an exclusive license agreement for JYB1904, a clinical-stage anti-immunoglobulin E monoclonal antibody.
The deal gives RAPT rights to develop and commercialize JYB1904, which has an RAPT designation of RPT904, globally except in mainland China, Hong Kong, Macau and Taiwan, the companies said.
They said that as consideration for the license, Shanghai Jemincare will get an upfront license fee of $35 million, additional payments of up to $672.5 million upon the achievement of several regulatory and commercial milestones, and royalties on future sales in the areas covered by the deal.
RAPT plans to start a phase 2b trial in food allergy in 2025 and Shanghai Jemincare is separately conducting phase 2 clinical trials in asthma and chronic spontaneous urticaria in China, the companies said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。